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We compared antibiotic prescribing for children with and
those without an underlying chronic condition associated with
increased risk for invasive pneumococcal disease. Children
with a chronic condition had significantly greater cumulative
exposure to antibiotics and higher rates of prescriptions per
person-year than those without a chronic condition; this population is at increased risk for the emergence of multidrug-resistant pathogens.
Keywords. antibiotic resistance; antibiotic stewardship;
antibiotic use; children’s health; physician; prescribing patterns.

Children with a specific underlying comorbid condition have
been recognized to be at increased risk of invasive pneumococcal
disease [1]. We hypothesized that those children might represent a
population likely to have disproportionate exposure to antibiotics
compared with children without such a condition and could represent a target population for interventions to reduce inappropriate antibiotic prescribing. We compared the cumulative burden of
antibiotic exposure and rates of antibiotic prescribing for children
with and those without a specific condition that predisposed them
to invasive pneumococcal disease during the first 6 years of life.
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METHODS

Data from the Truven Health Analytics MarketScan Commercial
Claims Database for the years 2007 to 2013 were used for the study.
MarketScan includes claims for inpatient and outpatient care from
more than 100 commercial health insurance plans covering working adults younger than 65 years and their dependents and represents nearly half of the US health insurance plans. Children born
in 2007 or 2008 with pharmacy coverage for the duration of their
enrollment in the health insurance plan were included and followed longitudinally from birth to either the end of the observation period (December 31, 2013) or until they dropped out of the
cohort (eg, changed insurers). The Boston University Institutional
Review Board deemed this project exempt from review.
The International Classification of Diseases, Ninth Revision,
and Current Procedural Terminology diagnosis and procedural codes were used to identify conditions recognized by
the American Academy of Pediatrics Committee on Infectious
Diseases as predisposing to invasive pneumococcal infection
[2]. Children with at least 1 inpatient or 2 outpatient records
documenting 1 of these specific chronic conditions were categorized as having that condition from the earliest coding occurrence. For analyses according to age, only children with full
enrollment during the corresponding age range were included.
Children were categorized as having a comorbid condition if
their condition was diagnosed before the age considered in the
analysis. For example, for the analysis of antibiotic prescribing
at the age of 2 years, only children diagnosed with a chronic
condition before their second birthday were included.
Prescription data were from outpatient visits only. We categorized antibiotics according to their National Drug Code and
evaluated use within 5 therapeutic classes, namely, penicillins,
cephalosporins, macrolides, sulfonamides, and fluoroquinolones. Cumulative antibiotic exposure was the sum of unique
drug prescriptions for each year of life and according to specific
chronic condition. The rate of antibiotic prescribing was calculated by dividing the total number of antibiotic prescriptions by
total person-time. To compare rates, we used the large-sample
χ2 test. We also performed a sensitivity analysis that excluded
conditions that could be an indication for chronic antibiotic
prophylaxis, and it did not change our results.
RESULTS

A total of 512 400 infants were enrolled in the study, and the average follow-up time was 2.8 years. Of these children, 17% were identified with 1 or more of the risk conditions included in our analysis
(Supplementary Table 1). Low birth weight (7.97%), recurrent
wheezing/asthma (6.01%), chronic heart disease (2.43%), and
chronic lung disease (2.38%) were the most common diagnoses.
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a chronic condition had significantly higher rates of antibiotic
prescriptions than children without any of the designated conditions (Supplementary Table 2). Children with chronic lung
disease (2.70 prescriptions), recurrent wheezing/asthma (2.43
prescriptions), low birth weight (1.87 prescriptions), or both
recurrent wheezing/asthma and low birth weight (2.87 prescriptions) had significantly higher prescribing rates than children without any of these conditions.
According to the average cumulative prescriptions by
6 years of age, penicillins were prescribed most often for children with and those without a chronic condition (6.31 and 4.45
prescriptions, respectively), followed by cephalosporins (3.20
and 2.00 prescriptions, respectively) and macrolides (2.99 and
1.52 prescriptions, respectively) (Supplementary Figure). The
mean and median durations of each prescription were comparable in the children without a chronic condition (9.7 and
9.9 days, respectively) and in those with a comorbidity (9.9
and 10 days, respectively). The proportion of children prescribed more than 28 or 60 days of antibiotics in each year of
life was greater in those with a designated comorbid condition
(Supplemental Table 3).

Figure 1. Cumulative number of antibiotic prescriptions for the first 6 years of life. (A) Mean antibiotic exposure between children with and those without
any chronic condition compared with that of the pooled cohort. (B) Mean antibiotic exposure for children with a specific chronic condition compared with
children without any chronic condition.
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Over the first 6 years of life, the average child received 9
antibiotic prescriptions (Figure 1). Children with a chronic
condition were prescribed antibiotics more intensively than
children without a chronic condition by their sixth birthday
(cumulative means: 12.50 vs 7.91 antibiotic prescriptions,
respectively). Prescribing between the 2 groups diverged soon
after birth. When stratified according to specific chronic condition, the average cumulative exposures to antibiotics by the
age of 6 years were 11.71 prescriptions for children with low
birth weight, 12.97 prescriptions for children with chronic heart
disease, 13.57 prescriptions for children with recurrent wheezing/asthma, and 15.99 prescriptions for children with chronic
lung disease. Children with both low birth weight and recurrent
wheezing/asthma had greater cumulative antibiotic exposure
(average, 16.95 prescriptions by 6 years of age) than those with
either condition alone.
The overall rate of antibiotic prescribing was 1.55 prescriptions per person-year. Children with a chronic condition
received 2.12 antibiotic prescriptions per person-year, whereas
those without a chronic condition were given 1.39 prescriptions
per person-year (P < .001). For each year of life, children with

DISCUSSION

CONCLUSION

Our analysis of a large claims database reveals that children with
a chronic condition that predisposes them to invasive pneumococcal infection are exposed to antibiotics more than 1.5 times
more often than children without such a condition. Children
with chronic lung disease or recurrent wheezing/asthma have
the highest antibiotic exposures, and this exposure is amplified
when more than 1 condition is present. Despite a declining incidence of pneumococcal disease in children after the introduction of first- and second-generation pneumococcal conjugate
vaccines [3] and decreasing rates of antibiotic prescribing associated with nationwide programs for judicious use of antibiotics
[4, 5], significantly higher rates of antibiotic prescribing were
documented for children with a comorbidity than for children
without a comorbidity.
Evidence supports the theory that higher exposure to
antibiotics in a specific geographic area results in a prevalence of antibiotic resistance among respiratory pathogens
that is higher than that in areas with lower exposure, which
suggests that children with increased risk for invasive pneumococcal disease might be a population at higher risk for
the emergence of resistant pathogens [6, 7]. The mechanisms proposed include unmasking of bacterial pathobionts
already present or acquisition of resistant pathogens during
treatment episodes [8].
Our study had several limitations. The database we used
tracks filled prescriptions, not actual use, so we cannot know
whether the children ingested all of their prescribed doses.
We also do not know if the prescriptions were appropriate.
Our sample did not include children insured by Medicaid,
who might exhibit different characteristics than those who
are commercially insured. Also, children with a chronic
condition might change insurers at different rates than the
balance of the population, which would make this longitudinal sample less representative. Finally, our data cannot
be generalized to all comorbid conditions, such as those
identified using the classification by Feudtner et al [9]. The
American Academy of Pediatrics classification includes
conditions that pose particular risk for invasive pneumococcal diseases, which we believe is appropriate when examining antibiotic use.

In summary, children in our study were exposed, on average, to
more than 9 antibiotic prescriptions from birth to the age of 6 years;
children with a chronic illness had significantly greater exposure
than those without a chronic condition. Targeted antibiotic stewardship in this population might identify inappropriate use that could be
reduced safely, and microbial surveillance could provide early warning of the emergence of new resistance among potential pathogens.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious
Diseases Society online.
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